135 results
S-3ASR
EX-5.2
AKRO
Akero Therapeutics Inc
10 May 24
Automatic shelf registration
4:57pm
such examination of law as we have deemed appropriate to give the opinion set forth below. We have relied, without independent verification, on certificates
S-3ASR
EX-4.3
AKRO
Akero Therapeutics Inc
10 May 24
Automatic shelf registration
4:57pm
amount in moneys or Governmental Obligations or a combination thereof, sufficient in the opinion of a nationally recognized firm of independent … no responsibility for any calculations hereunder and shall be entitled to conclusively rely on the calculations of the Company without any independent
S-3ASR
EX-23.1
AKRO
Akero Therapeutics Inc
10 May 24
Automatic shelf registration
4:57pm
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in this Registration Statement
S-3ASR
EX-4.2
AKRO
Akero Therapeutics Inc
10 May 24
Automatic shelf registration
4:57pm
of independent public accountants expressed in a written certification thereof delivered to the Trustee, to pay at maturity or upon redemption all Securities … independent verification or investigation.
IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed all as of the day and year
S-3ASR
AKRO
Akero Therapeutics Inc
10 May 24
Automatic shelf registration
4:57pm
transactions or otherwise. Any of these activities may stabilize or maintain the market price of the securities above independent market levels. Any … , and the effectiveness of Akero Therapeutics, Inc.’s internal control over financial reporting have been audited by Deloitte & Touche LLP, an independent registered
S-3ASR
EX-5.1
7r1oku94e40lgcn
10 May 24
Automatic shelf registration
4:57pm
PRE 14A
3wrk67bsg3ywj3
16 Apr 24
Preliminary proxy
4:30pm
8-K
EX-5.1
754282y hx0
6 Mar 24
Entry into a Material Definitive Agreement
5:25pm
8-K
EX-1.1
9cn7i0e
6 Mar 24
Entry into a Material Definitive Agreement
5:25pm
424B5
9u13oqcrhyx 4pjwx
6 Mar 24
Prospectus supplement for primary offering
5:16pm
424B5
277nmqsg2 mlm4265irx
4 Mar 24
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.2
5qb of4gd
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
S-8
EX-5.1
pghq9
29 Feb 24
Registration of securities for employees
4:42pm
S-8
EX-23.1
2h1oqs yj335bio2s
29 Feb 24
Registration of securities for employees
4:42pm
S-8
pq59n22g mcqmdzx7
29 Feb 24
Registration of securities for employees
4:42pm